Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. MoonLake Immunotherapeutics is the next stock on our list.

TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a price target of $10, up from $8. The firm noted that sonelokimab’s advancement into Phase 3 for palmoplantar pustulosis provides an additional opportunity, but it continues to view significant approvability risk in hidradenitis suppurativa. Given VELA-2’s failure to meet its primary endpoint, Goldman Sachs does not believe the FDA’s procedural guidance meaningfully reduces approval uncertainty.

Separately, earlier this month, on January 9, H.C. Wainwright raised the price target on MoonLake Immunotherapeutics (NASDAQ:MLTX) to $32 from $26 and maintained a Buy rating. The firm noted that the outcome of the FDA Type B meeting provides a defined path toward regulatory registration.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical‑stage biopharmaceutical company that develops revolutionary Nanobody therapies to treat inflammatory skin and joint diseases. Its primary asset, sonelokimab, targets IL‑17A and IL‑17F to reduce inflammation in disorders like hidradenitis suppurativa and psoriatic arthritis.

While we acknowledge the potential of MLTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.